Adverse Effects | Topics

 
OQ011 Yields Positive Safety and Efficacy in Treating Hand-Foot Skin Reaction–Related Pain
February 22, 2022

OQ011, a topical ointment for hand-foot skin reaction-related pain, yielded positive safety and efficacy in part 1 of 2 phase 2 NOVA-II trial.

FDA Greenlights Label Update for Use of Steroids Following Axi-Cel for Management of CRS
January 31, 2022

A label update for the CAR T-cell therapy product axicabtagene ciloleucel has been approved by the FDA to allow for use of prophylactic corticosteroid to manage cytokine release syndrome.

Prophylactic Fosnetupitant Yields Noninferiority and Favorable Safety vs Fosaprepitant for Chemo-Induced Nausea and Vomiting
January 29, 2022

Fosnetupitant demonstrated non-inferiority and a favorable safety profile vs fosaprepitant for chemotherapy-induced nausea and vomiting.

Association Found Between Occurrence of Cutaneous Immune-Related AEs and Response to Immunotherapy and Survival
January 14, 2022

Investigators reported that the development of cutaneous immune-related adverse effects has a strong association with response in survival among patients with cancer treated with immunotherapy.

FDA Issues Complete Response Letter to Plinabulin Application for Prevention of Chemotherapy-Induced Neutropenia
December 02, 2021

A complete response letter has been issued to BeyondSpring Pharmaceuticals for plinabulin plus granulocyte colony-stimulating factor for the prevention of chemotherapy-induced neutropenia.

EC-18 Yields Positive Results for Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer
October 21, 2021

A phase 2 trial examining the use of small molecule immunomodulator EC-18 in patients with head and neck cancer experiencing chemoradiation-induced oral mucositis met its primary and secondary end points.

FDA Approves Luspatercept to Treat Anemia in Patients with Lower-Risk MDS
April 06, 2020

The FDA approved the first and only erythroid maturation agent for the treatment of anemia in patients with lower-risk myelodysplastic syndromes.

FDA Approves Luspatercept to Treat Beta Thalassemia–Associated Anemia
November 08, 2019

The agency approved the first and only FDA-approved erythroid maturation agent to treat anemia in adult patients with beta thalassemia who require regular red blood cell transfusions.

Researchers Make Anemia Discovery That May Provide New Targets for Therapy
February 05, 2018

A new study has revealed that the amount of iron in the blood affects the amount of the Scribble protein, which appears to control receptors that create new red blood cells.

New Insights Into Sickle Cell Disease Point to Novel Treatment Paradigms
January 29, 2018

Using a super computer, a team at Brown University has created a model of sickle cell anemia, devising a method that could help researchers assess and evaluate treatments to combat sickle cell disease.